EHA23 Insights into the Changing Landscape of Myeloma Treatments
In his MEDtalk from EHA23, Fredrik Schjesvold, leader of the Oslo Myeloma Center, Oslo University Hospital, discusses the dynamic changes in the landscape of myeloma treatments. Additionally, Fredrik nuances the recent data on the BCMA antibody belantamab mafodotin, highlighting its advantages in terms of response duration and depth, making it a valuable option for late-line treatment.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in